Please enable JavaScript to continue using this application.

Compare $IMVT vs $RYTM | Chartloom

Compare

$IMVT vs $RYTM

Immunovant Inc · Rhythm Pharmaceuticals Inc

IMVT

Immunovant Inc

RYTM

Rhythm Pharmaceuticals Inc

Compare $IMVT vs $RYTM

Comparing Immunovant Inc and Rhythm Pharmaceuticals Inc

IMVTImmunovant Inc

RYTMRhythm Pharmaceuticals Inc

IMVTImmunovant Inc

Market cap

$6.29B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

17.6%

52W performance

89.5%

FCF yield

-6.6%

RYTMRhythm Pharmaceuticals Inc

Market cap

$6.22B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.08x

Rev growth (TTM)

53.5%

YTD performance

-13.6%

52W performance

-9.4%

FCF yield

-1.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IMVT

RYTM

Detailed metrics comparison

IMVT

Immunovant Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

IMVT$6.29B

RYTM$6.22B

Enterprise Value

IMVT$5.49B

RYTM$6.26B

Price

IMVT$30.47

RYTM$90.78

P/E Ratio

IMVTN/A

RYTMN/A

P/S Ratio

IMVT0.00x

RYTM25.93x

EV/Sales

IMVT0.00x

RYTM26.10x

EV/EBITDA

IMVT0.00x

RYTM0.00x

P/B Ratio

IMVT9.44x

RYTM29.41x

P/FCF Ratio

IMVTN/A

RYTMN/A

EV/FCF

IMVT-13.25x

RYTM-58.90x

PEG Ratio

IMVTN/A

RYTMN/A

Forward P/E (NTM)

IMVTN/A

RYTMN/A

Forward P/S (NTM)

IMVTN/A

RYTM15.08x

Revenue (TTM)

IMVT$0

RYTM$240M

Revenue Growth (YoY)

IMVTN/A

RYTM53.5%

Forward Rev Growth

IMVT546.2%

RYTM77.4%

Gross Margin (TTM)

IMVT0.0%

RYTM70.9%

Operating Margin (TTM)

IMVT0.0%

RYTM0.0%

EBITDA Margin (TTM)

IMVT0.0%

RYTM-83.2%

Net Margin (TTM)

IMVT0.0%

RYTM-87.6%

FCF Margin (TTM)

IMVTN/A

RYTM-44.3%

Net Income (TTM)

IMVT$-538M

RYTM$-210M

FCF (TTM)

IMVT$-414M

RYTM$-106M

EPS (TTM)

IMVT-$2.62

RYTM-$3.06

ROE (TTM)

IMVT-6959.0%

RYTM-8048.0%

ROA (TTM)

IMVT-6250.0%

RYTM-4400.0%

ROIC (TTM)

IMVT-6959.0%

RYTM-5656.0%

Cash

IMVT$798M

RYTM$66M

Debt

IMVT$0

RYTM$106M

Net Cash/Debt

IMVT$798M

RYTM$-40M

Current Ratio (TTM)

IMVT7.27x

RYTM3.45x

Quick Ratio (TTM)

IMVT6.82x

RYTM3.00x

Debt/Equity (TTM)

IMVT0.00x

RYTM0.49x

Debt/Assets (TTM)

IMVT0.0%

RYTM0.0%

Interest Coverage (TTM)

IMVTN/A

RYTMN/A

Net Debt/EBITDA (TTM)

IMVT0.00x

RYTM0.00x

Beta

IMVT0.92

RYTM2.13

52W Performance

IMVT89.5%

RYTM-9.4%

YTD Performance

IMVT17.6%

RYTM-13.6%

% from 52W High

IMVT-32.9%

RYTM-25.7%

% from 52W Low

IMVT89.5%

RYTM21.9%

Asset Turnover (TTM)

IMVT0.00x

RYTM0.51x

FCF Yield (TTM)

IMVT-6.6%

RYTM-1.7%

Earnings Yield (TTM)

IMVT-8.6%

RYTM-3.4%

Dividend Yield (TTM)

IMVTN/A

RYTMN/A

Rule of 40

IMVT0.0

RYTM9.2

EV/GP/RG

IMVTN/A

RYTM0.49

Ticker research

View IMVT research View RYTM research

Metric	IMVT Immunovant Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$6.29B	$6.22B
Enterprise Value	$5.49B	$6.26B
Price	$30.47	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	25.93x
EV/Sales	0.00x	26.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	9.44x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-13.25x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	15.08x
Revenue & Growth
Revenue (TTM)	$0	$240M
Revenue Growth (YoY)	N/A	53.5%
Forward Rev Growth	546.2%	77.4%
Profitability
Gross Margin (TTM)	0.0%	70.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-83.2%
Net Margin (TTM)	0.0%	-87.6%
FCF Margin (TTM)	N/A	-44.3%
Net Income (TTM)	$-538M	$-210M
FCF (TTM)	$-414M	$-106M
EPS (TTM)	-$2.62	-$3.06
ROE (TTM)	-6959.0%	-8048.0%
ROA (TTM)	-6250.0%	-4400.0%
ROIC (TTM)	-6959.0%	-5656.0%
Financial Health
Cash	$798M	$66M
Debt	$0	$106M
Net Cash/Debt	$798M	$-40M
Current Ratio (TTM)	7.27x	3.45x
Quick Ratio (TTM)	6.82x	3.00x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	2.13
52W Performance	89.5%	-9.4%
YTD Performance	17.6%	-13.6%
% from 52W High	-32.9%	-25.7%
% from 52W Low	89.5%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.51x
FCF Yield (TTM)	-6.6%	-1.7%
Earnings Yield (TTM)	-8.6%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	9.2
EV/GP/RG	N/A	0.49
Ticker research	View IMVT research	View RYTM research

Valuation

P/S Ratio

IMVT

0.00x

RYTM

25.93x

EV/FCF

RYTM

-58.90x

IMVT

-13.25x

Growth & revenue

Revenue Growth TTM

RYTM

53.5%

Forward Revenue Growth

IMVT

546.2%

RYTM

77.4%

Profitability & performance

Gross Margin

RYTM

70.9%

IMVT

0.0%

ROE

IMVT

-6959.0%

RYTM

-8048.0%

FCF Yield %

RYTM

-1.7%

IMVT

-6.6%

52-Week Performance

IMVT

89.5%

RYTM

-9.4%

Detailed metrics comparison

IMVT

Immunovant Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

IMVT$6.29B

RYTM$6.22B

Enterprise Value

IMVT$5.49B

RYTM$6.26B

Price

IMVT$30.47

RYTM$90.78

P/E Ratio

IMVTN/A

RYTMN/A

P/S Ratio

IMVT0.00x

RYTM25.93x

EV/Sales

IMVT0.00x

RYTM26.10x

EV/EBITDA

IMVT0.00x

RYTM0.00x

P/B Ratio

IMVT9.44x

RYTM29.41x

P/FCF Ratio

IMVTN/A

RYTMN/A

EV/FCF

IMVT-13.25x

RYTM-58.90x

PEG Ratio

IMVTN/A

RYTMN/A

Forward P/E (NTM)

IMVTN/A

RYTMN/A

Forward P/S (NTM)

IMVTN/A

RYTM15.08x

Revenue (TTM)

IMVT$0

RYTM$240M

Revenue Growth (YoY)

IMVTN/A

RYTM53.5%

Forward Rev Growth

IMVT546.2%

RYTM77.4%

Gross Margin (TTM)

IMVT0.0%

RYTM70.9%

Operating Margin (TTM)

IMVT0.0%

RYTM0.0%

EBITDA Margin (TTM)

IMVT0.0%

RYTM-83.2%

Net Margin (TTM)

IMVT0.0%

RYTM-87.6%

FCF Margin (TTM)

IMVTN/A

RYTM-44.3%

Net Income (TTM)

IMVT$-538M

RYTM$-210M

FCF (TTM)

IMVT$-414M

RYTM$-106M

EPS (TTM)

IMVT-$2.62

RYTM-$3.06

ROE (TTM)

IMVT-6959.0%

RYTM-8048.0%

ROA (TTM)

IMVT-6250.0%

RYTM-4400.0%

ROIC (TTM)

IMVT-6959.0%

RYTM-5656.0%

Cash

IMVT$798M

RYTM$66M

Debt

IMVT$0

RYTM$106M

Net Cash/Debt

IMVT$798M

RYTM$-40M

Current Ratio (TTM)

IMVT7.27x

RYTM3.45x

Quick Ratio (TTM)

IMVT6.82x

RYTM3.00x

Debt/Equity (TTM)

IMVT0.00x

RYTM0.49x

Debt/Assets (TTM)

IMVT0.0%

RYTM0.0%

Interest Coverage (TTM)

IMVTN/A

RYTMN/A

Net Debt/EBITDA (TTM)

IMVT0.00x

RYTM0.00x

Beta

IMVT0.92

RYTM2.13

52W Performance

IMVT89.5%

RYTM-9.4%

YTD Performance

IMVT17.6%

RYTM-13.6%

% from 52W High

IMVT-32.9%

RYTM-25.7%

% from 52W Low

IMVT89.5%

RYTM21.9%

Asset Turnover (TTM)

IMVT0.00x

RYTM0.51x

FCF Yield (TTM)

IMVT-6.6%

RYTM-1.7%

Earnings Yield (TTM)

IMVT-8.6%

RYTM-3.4%

Dividend Yield (TTM)

IMVTN/A

RYTMN/A

Rule of 40

IMVT0.0

RYTM9.2

EV/GP/RG

IMVTN/A

RYTM0.49

Ticker research

View IMVT research View RYTM research

Metric	IMVT Immunovant Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$6.29B	$6.22B
Enterprise Value	$5.49B	$6.26B
Price	$30.47	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	25.93x
EV/Sales	0.00x	26.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	9.44x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-13.25x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	15.08x
Revenue & Growth
Revenue (TTM)	$0	$240M
Revenue Growth (YoY)	N/A	53.5%
Forward Rev Growth	546.2%	77.4%
Profitability
Gross Margin (TTM)	0.0%	70.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-83.2%
Net Margin (TTM)	0.0%	-87.6%
FCF Margin (TTM)	N/A	-44.3%
Net Income (TTM)	$-538M	$-210M
FCF (TTM)	$-414M	$-106M
EPS (TTM)	-$2.62	-$3.06
ROE (TTM)	-6959.0%	-8048.0%
ROA (TTM)	-6250.0%	-4400.0%
ROIC (TTM)	-6959.0%	-5656.0%
Financial Health
Cash	$798M	$66M
Debt	$0	$106M
Net Cash/Debt	$798M	$-40M
Current Ratio (TTM)	7.27x	3.45x
Quick Ratio (TTM)	6.82x	3.00x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.92	2.13
52W Performance	89.5%	-9.4%
YTD Performance	17.6%	-13.6%
% from 52W High	-32.9%	-25.7%
% from 52W Low	89.5%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.51x
FCF Yield (TTM)	-6.6%	-1.7%
Earnings Yield (TTM)	-8.6%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	9.2
EV/GP/RG	N/A	0.49
Ticker research	View IMVT research	View RYTM research